Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Wheeler Bio
Sort By
Newest First
1 / 2
1 / 2
Leap-In Transposase
Leveraging Innovative Transposase Technology for a Highly Reliable and Productive CMC Platform
Wheeler Bio
PAO-06-24-CL-05
May 30, 2024
The PHASE Platform
How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success
Wheeler Bio
PAO-05-24-CL-01
May 08, 2024
Commitment to ESG Principles
How can pharmaceutical and biopharmaceutical companies demonstrate their commitment to ESG principles in manufacturing?
Pharma's Almanac
PAO-03-24-CL-03
March 08, 2024
Accelerating Product Development
What strategies are being employed to accelerate product development and commercialization without compromising quality?
Pharma's Almanac
PAO-03-24-CL-02
March 08, 2024
Portable CMC
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
Wheeler Bio
PR-M02-29-01
February 29, 2024
CMC
Revolutionizing Early-Stage Biopharma Development: Introducing Wheeler Bio's Portable CMC® Platform
Wheeler Bio
PAO-12-23-CL-04
February 08, 2024
Supply Chain
Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience
Tim Tyson; Jesse McCool, Ph.D.; Russell Harris; Yongkwan Ma
TriRx Pharmaceutical Services
PTV-12-23-CL-02
December 12, 2023
Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC
Wheeler Bio
PR-M11-23-01
November 08, 2023
Wheeler Bio Announces Grand Opening of Biomanufacturing Facility
Wheeler Bio
PR-M10-23-01
October 05, 2023
Business Leadership
Wheeler Bio Appoints Marc Helouin as Chief Quality and Regulatory Officer
Wheeler Bio
PR-M08-23-01
August 15, 2023
CMC
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.
Wheeler Bio
PAO-07-23-CL-05
July 26, 2023
Leadership
Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer
Wheeler Bio
PR-M06-23-02
June 06, 2023
Biologics Testing Lab
Wheeler Bio and Charles River Laboratories Announce Agreement to Build and Operate RightSource℠ Laboratory
Wheeler Bio
PR-M06-23-01
May 31, 2023
Cell Line Development Technology
Wheeler Bio Licenses ATUM’s Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering
Wheeler Bio
PR-M11-22-09
November 30, 2022
Series A Funding
Wheeler Bio Announces Initial Closing of Series A Round Supporting New Biologics Drug Substance GMP Expansion In Oklahoma
Wheeler Bio
PR-M10-22-02
October 05, 2022
Leadership
Wheeler Bio Announces Roger Lias, Ph.D. as President and Chief Operating Officer
Wheeler Bio
PR-M09-22-05
September 22, 2022
Pharma 4.0
Applying an Advanced Pharma 4.0 Perspective to Design the Facility of the Future
Yuk Chun Chiu, M.S.E.; Dawn Wofford; Patricia Robbins; Yvonne Duckworth; Steve Attig
Wheeler Bio
PAO-06-022-CL-11
September 08, 2022
Cell Line Development
Integrating Cell Line and CMC Development
Stephen Hamilton, Ph.D.; Mike Brem
Wheeler Bio
PAO-06-022-CL-12
September 02, 2022
Cell Line Development
Wheeler Bio Integrates the Solentim® Ecosystem by Advanced Instruments to Deliver the Highest Level of Consistency Across Their Cell Line Development Workflow
Advanced Instruments
PR-M06-22-04
June 14, 2022
Digitalization
Reducing Time to IND, Increasing Quality, and Building Trust through Shared Data
David Alvaro, Ph.D.; Christa Short; Jesse McCool, Ph.D.; Lance Johnson; Markus Gershater, Ph.D.; Michael Sokolov, Ph.D.; Yuk Chun Chiu, M.S.E.; Guy Levy-Yurista, Ph.D.; David Schmidt, M.B.A., M.Sc.
Pharma's Almanac
PAO-05-022-CL-01
May 18, 2022
